Use of the Nuclear Matrix Protein 22 BladderChek Test for the Detection of Primary and Recurrent Urothelial Carcinoma

Table 4

The sensitivity of urine tests for the diagnosis of primary urothelial carcinoma stratified by tumor site, invasivity, and grade.

	NMP22 positive; Number (%)	Cytology positive; Number (%)	value
Site			0.010^†; 0.772^‡; 0.013^∮; 0.024^§
Bladder	21 (30.9%)
Ureter	4 (26.7%)
Kidney	9 (69.2%)
Multisites	5 (71.4%)
Invasivity			0.005
Nonmuscle invasive	18 (27.7%)
Muscle invasive	21 (55.3%)
Grade			0.001^&; 0.006^※
PNLMP	0 (0.0%)
Low	6 (20.7%)
High	33 (50.8%)
^#
Site			0.635
Bladder		13 (59.1%)
Ureter		4 (36.4%)
Kidney		6 (60.0%)
Multisites		3 (60.0%)
Invasivity			0.790
Nonmuscle invasive		12 (52.2%)
Muscle invasive		14 (56.0%)
Grade			0.041
Low		3 (27.3%)
High		23 (62.2%)

Note: patients performed the NMP22 BladderChek tests; ^#patients performed the NMP22 BladderChek tests and urine cytology tests; PNLMP, papillary neoplasm of low malignant potential; categorical variables were analyzed with a or Fisher’s exact test; ^†the sensitivity of the NMP22 BladderChek test was compared among bladder UC, ureter UC, kidney UC, and multisites UC; ^‡bladder UC vs. ureter UC; ^∮bladder UC vs. kidney UC; ^§ureter UC vs. kidney UC; ^&the sensitivity of the NMP22 BladderChek test was compared among PNLMP UC, low-grade UC, and high-grade UC; ^※low-grade UC vs. high-grade UC.